Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

被引：1

作者：

Fiala, Ondrej ^{[1
,2
]}

Massari, Francesco ^{[3
,4
]}

Basso, Umberto ^{[5
]}

Giannatempo, Patrizia ^{[6
]}

Grande, Enrique ^{[7
]}

Buti, Sebastiano ^{[8
,9
]}

Myint, Zin W. ^{[10
]}

De Giorgi, Ugo ^{[11
]}

Pichler, Renate ^{[12
]}

Grillone, Francesco ^{[13
]}

Urun, Yuksel ^{[14
]}

Calabro, Fabio ^{[15
]}

Bourlon, Maria T. ^{[16
,17
]}

Galli, Luca ^{[18
]}

Kanesvaran, Ravindran ^{[19
]}

Roviello, Giandomenico ^{[20
]}

Kucharz, Jakub ^{[21
]}

Rizzo, Mimma ^{[22
]}

Park, Se Hoon ^{[23
]}

Cerbone, Linda ^{[24
]}

Seront, Emmanuel ^{[25
]}

Messina, Carlo ^{[26
]}

Molina-Cerrillo, Javier ^{[27
]}

Santini, Daniele ^{[28
]}

Yano, Akihiro ^{[29
]}

Incorvaia, Lorena ^{[30
]}

Catalano, Martina ^{[19
]}

Pinto, Alvaro ^{[31
]}

Formisano, Luigi ^{[32
]}

Soares, Andrey ^{[33
,34
]}

Facchini, Gaetano ^{[35
]}

Fornarini, Giuseppe ^{[36
]}

Poprach, Alexandr ^{[37
,38
]}

Rebuzzi, Sara Elena ^{[39
,40
]}

Nasso, Cecilia ^{[41
]}

Spinelli, Gian Paolo ^{[42
]}

Angel, Martin ^{[43
]}

Stellato, Marco ^{[6
]}

Tural, Deniz ^{[44
]}

Aurilio, Gaetano ^{[45
]}

Epstein, Ilana ^{[46
]}

Carrozza, Francesco ^{[47
]}

Monteiro, Fernando Sabino Marques ^{[48
,49
]}

Benedetti, Giovanni ^{[50
]}

Buchler, Tomas ^{[51
,52
]}

Ortega, Cinzia ^{[53
]}

Zakopoulou, Roubini ^{[54
]}

Battelli, Nicola ^{[55
]}

Porta, Camillo ^{[56
]}

Bellmunt, Joaquin ^{[46
,57
]}

机构：

[1] Charles Univ Prague, Univ Hosp Pilsen, Fac Med, Dept Oncol & Radiotherapeut, Alej Svobody 80, Plzen 30460, Czech Republic

[2] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic

[3] IRCCS Azienda Ospedaliero Univ Bologna, Med Oncol, Bologna, Italy

[4] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy

[5] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Med Oncol Unit 1, I-35128 Padua, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Via Giacomo Venezian 1, Milan, Italy

[7] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[8] Univ Parma, Dept Med & Surg, Parma, Italy

[9] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[10] Univ Kentucky, Markey Canc Ctr, Dept Internal Med, Div Med Oncol, Lexington, KY 40506 USA

[11] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Meldola, Italy

[12] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria

[13] Unita Operativa Oncol Presidio Pugliese Ciaccio Az, Catanzaro, Italy

[14] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkiye

[15] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[16] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hemato Oncol, Mexico City, Mexico

[17] Univ Panamericana, Escuela Med, Mexico City, DF, Mexico

[18] Azienda Ospedaliero Univ Pisana, Med Oncol Unit 2, Pisa, Italy

[19] Natl Canc Ctr Singapore, Div Med Oncol, Singapore City, Singapore

[20] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Viale Pieraccini 6, I-50139 Florence, Italy

[21] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Uro oncol, Warsaw, Poland

[22] Univ Consorziale Policlin Bari, Azienda Ospedaliera, Med Oncol Unit, Bari, Italy

[23] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[24] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy

[25] Clin Univ St Luc, Dept Med Oncol, Brussels, Belgium

[26] ARNAS Civ, Oncol Unit, Palermo, Italy

[27] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[28] Policlin Umberto 1, Oncol Dip Sci & Biotecnol Med Chirurg, Rome, Italy

[29] Saitama Med Univ, Saitama Med Ctr, Dept Urol, Saitama, Japan

[30] Univ Palermo, Dept Precis Med Med, Sect Med Oncol, Surg & Cit Care Me Pre C C, Palermo, Italy

[31] Hosp Univ La Paz, Serv Oncol, Madrid, Spain

[32] Univ Naples Federico II, Dept Med & Surg, Naples, Italy

[33] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil

[34] Ctr Paulista Oncol Oncoclin, Sao Paulo, SP, Brazil

[35] S Maria Grazie Hosp, ASL NA2 NORD, Oncol Unit, Naples, Italy

[36] IRCCS Osped Policlin San Martino, Genoa, Italy

[37] Masaryk Mem Canc Inst, Brno, Czech Republic

[38] Masaryk Univ, Fac Med, Brno, Czech Republic

[39] Osped San Paolo, Med Oncol Unit, Savona, Italy

[40] Univ Genoa, Dept Internal Md & Med Specialties Di M I, Genoa, Italy

[41] Osped Santa Corona, Med Oncol, Pietra Ligure, Italy

[42] UOC Oncol Territoriale Ausl Latina, Aprilia, Italy

[43] Alexander Fleming Inst, Genitourinary Oncol Unit, Clin Oncol, Buenos Aires, Argentina

[44] Bakirkoy Dr SadiKonuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye

[45] IEO European Inst Oncol IRCCS, Div Canc Prevent & Genet, Milan, Italy

[46] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[47] Santa Maria Croci Hosp, AUSL Romagna, Dept Oncol & Hematol, Oncol Unit, Ravenna, Italy

[48] Hosp Sirio Libanes, Brasilia, DF, Brazil

[49] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil

[50] Osped Civitanova Marche, UO Oncol, Civitanova Marche, Italy

来源：

TARGETED ONCOLOGY | 2024年 / 19卷 / 06期

关键词：

MULTICENTER; PEMBROLIZUMAB; CISPLATIN; THERAPY; CANCER;

D O I：

10.1007/s11523-024-01099-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Enfortumab vedotin (EV) has been approved for the treatment of patients with locally advanced/metastatic urothelial carcinoma (la/mUC) who previously received platinum-based chemotherapy followed by immune checkpoint inhibitors. However, the pivotal clinical trials did not include patients previously treated with avelumab maintenance therapy. Objective The aim of the present retrospective analysis was to assess the effectiveness of EV following avelumab in patients with mUC enrolled in the ARON-2EV study. Patients and Methods The study included 182 patients with mUC treated with EV following avelumab maintenance. The primary objective was to assess clinical outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and duration of response (DoR). Statistical analysis involved Fisher exact test, Kaplan-Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Results Median OS and PFS were 12.7 (95% CI 10.2-14.1) and 7.9 (95% CI 6.4-9.9) months, respectively. Complete response (CR) was achieved in 5% and partial response (PR) in 34% of patients, with an ORR of 39%. The DoR in patients who achieved CR/PR was 10.9 months (95% CI 8.1-11.4). The incidence of grade >= 3 peripheral neuropathy and skin rash was 9%, followed by 8% of grade >= 3 diarrhea and 4% of grade >= 3 hyperglycemia. Conclusions The results of our large international retrospective study confirm the effectiveness of EV and endorse its use in the population of patients with mUC treated with EV following the frontline platinum-based chemotherapy and subsequent maintenance treatment with avelumab.

引用

页码：905 / 915

页数：11

共 21 条

[1] Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
Barthelemy, Philippe
Loriot, Yohann
Thibault, Constance
Gross-Goupil, Marine
Eymard, Jean Christophe
Voog, Eric
Abraham Jaillon, Christine
Le Moulec, Sylvestre
Chasseray, Matthieu
Gobert, Aurelien
Auberger, Benjamin
Viala, Caroline
Cabart, Mathilde
Kazan, Eyad
Lorgis, Veronique
Hilgers, Werner
Josse, Constant
Lambert, Prisca
Solbes, Marie-Noelle
Flechon, Aude
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 561 - 561
[2] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[3] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
De Santis, Maria
Bellmunt, Joaquim
Mead, Graham
Kerst, J. Martijn
Leahy, Michael
Maroto, Pablo
Gil, Thierry
Marreaud, Sandrine
Daugaard, Gedske
Skoneczna, Iwona
Collette, Sandra
Lorent, Julie
de Wit, Ronald
Sylvester, Richard
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 191 - 199
[4] evs.nci.nih.gov, US
[5] Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
Fukuokaya, Wataru
Koike, Yuhei
Yata, Yuji
Komura, Kazumasa
Uchimoto, Taizo
Tsujino, Takuya
Saruta, Masanobu
Takahara, Kiyoshi
Fujita, Kazutoshi
Minami, Takafumi
Adachi, Takahiro
Hirasawa, Yosuke
Hashimoto, Takeshi
Ohno, Yoshio
Uemura, Hirotsugu
Shiroki, Ryoichi
Azuma, Haruhito
Kimura, Takahiro
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 342 - 347
[6] Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Hirasawa, Yosuke
Adachi, Takahiro
Hashimoto, Takeshi
Fukuokaya, Wataru
Koike, Yuhei
Yata, Yuji
Komura, Kazumasa
Uchimoto, Taizo
Tsujino, Takuya
Nishimura, Kazuki
Takahara, Kiyoshi
Saruta, Masanobu
Fujita, Kazutoshi
Hashimoto, Mamoru
Uemura, Hirotsugu
Shiroki, Ryoichi
Azuma, Takashi
Kimura, Takahiro
Ohno, Yoshio
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
[7] Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Kawahara, Takashi
Hasizume, Akihito
Uemura, Koichi
Yamaguchi, Katsuya
Ito, Hiroki
Takeshima, Teppei
Hasumi, Hisashi
Teranishi, Jun-ichi
Ousaka, Kimito
Makiyama, Kazuhide
Uemura, Hiroji
[J]. CANCERS, 2023, 15 (17)
[8] Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Koshkin, Vadim S.
Henderson, Nicholas
James, Marihella
Natesan, Divya
Freeman, Dory
Nizam, Amanda
Su, Christopher T.
Khaki, Ali Raza
Osterman, Chelsea K.
Glover, Michael J.
Chiang, Ryan
Makrakis, Dimitrios
Talukder, Rafee
Lemke, Emily
Olsen, T. Anders
Jain, Jayanshu
Jang, Albert
Ali, Alicia
Jindal, Tanya
Chou, Jonathan
Friedlander, Terence W.
Hoimes, Christopher
Basu, Arnab
Zakharia, Yousef
Barata, Pedro C.
Bilen, Mehmet A.
Emamekhoo, Hamid
Davis, Nancy B.
Shah, Sumit A.
Milowsky, Matthew I.
Gupta, Shilpa
Campbell, Matthew T.
Grivas, Petros
Sonpavde, Guru P.
Kilari, Deepak
Alva, Ajjai S.
[J]. CANCER, 2022, 128 (06) : 1194 - 1205
[9] Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.
Nizam, Amanda
Jindal, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Davidsohn, Matthew P.
Nguyen, Charles B.
Oh, Eugene
Taylor, Amy K.
Lemke, Emily
Kilari, Deepak
Hoimes, Christopher J.
Emamekhoo, Hamid
Gupta, Shilpa
Bellmunt, Joaquim
Grivas, Petros
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 537 - 537
[10] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Powles, T.
Valderrama, B. P.
Gupta, S.
Bedke, J.
Kikuchi, E.
Hoffman-Censits, J.
Iyer, G.
Vulsteke, C.
Park, S. H.
Shin, S. J.
Castellano, D.
Fornarini, G.
Li, J. R.
Guemues, M.
Mar, N.
Loriot, Y.
Flechon, A.
Duran, I
Drakaki, A.
Narayanan, S.
Yu, X.
Gorla, S.
Moreno, B. Homet
van der Heijden, M. S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10) : 875 - 888

← 1 2 3 →